BR112019001035A2 - beenato de rotigotina, e método de preparação e uso do mesmo - Google Patents

beenato de rotigotina, e método de preparação e uso do mesmo

Info

Publication number
BR112019001035A2
BR112019001035A2 BR112019001035-1A BR112019001035A BR112019001035A2 BR 112019001035 A2 BR112019001035 A2 BR 112019001035A2 BR 112019001035 A BR112019001035 A BR 112019001035A BR 112019001035 A2 BR112019001035 A2 BR 112019001035A2
Authority
BR
Brazil
Prior art keywords
rotigotine
beenate
behenate
preparation
manufacture
Prior art date
Application number
BR112019001035-1A
Other languages
English (en)
Inventor
Yang Mina
Jiang Yongtao
Meng Ying
Wang Tao
Qian Xu Qian
Shao Xin
Sha Chunjie
Original Assignee
Shandong Luye Pharmaceutical Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co.,Ltd. filed Critical Shandong Luye Pharmaceutical Co.,Ltd.
Publication of BR112019001035A2 publication Critical patent/BR112019001035A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

a presente invenção refere-se a um beenato de rotigotina e um método de fabricação e aplicação do mesmo, e proporciona um método para a fabricação do beenato de rotigotina e uma aplicação do beenato de rotigotina no tratamento de uma doença relacionada com um receptor de dopamina. a estrutura do beenato de rotigotina é representada pela fórmula i. as flutuações da concentração no plasma do beenato de rotigotina in vivo são pequenas. o beenato de rotigotina pode manter uma concentração plasmática eficaz por um período prolongado, tem alta biodisponibilidade e pode alcançar o efeito de liberação estendida, eficaz e estável.
BR112019001035-1A 2016-07-21 2016-07-21 beenato de rotigotina, e método de preparação e uso do mesmo BR112019001035A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/090803 WO2018014277A1 (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Publications (1)

Publication Number Publication Date
BR112019001035A2 true BR112019001035A2 (pt) 2019-04-30

Family

ID=60992805

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001035-1A BR112019001035A2 (pt) 2016-07-21 2016-07-21 beenato de rotigotina, e método de preparação e uso do mesmo

Country Status (15)

Country Link
US (2) US10669249B2 (pt)
EP (1) EP3489227B1 (pt)
JP (1) JP6751208B2 (pt)
KR (1) KR20190031314A (pt)
CN (1) CN109415335B (pt)
AU (1) AU2016415408B2 (pt)
BR (1) BR112019001035A2 (pt)
CA (1) CA3030043C (pt)
ES (1) ES2855976T3 (pt)
MY (1) MY195897A (pt)
PH (1) PH12018550212A1 (pt)
PL (1) PL3489227T3 (pt)
RU (1) RU2717542C9 (pt)
SG (1) SG11201811543XA (pt)
WO (1) WO2018014277A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
CN108341798B (zh) * 2017-01-23 2021-05-25 沈阳药科大学 罗替戈汀衍生物及其制备和应用
EP4039678A4 (en) 2019-09-30 2023-09-27 Geneora Pharma (Shijiazhuang) Co., Ltd. CONNECTION AND PRODUCTION METHOD AND USE THEREOF
WO2022089408A1 (zh) 2020-10-27 2022-05-05 广州市恒诺康医药科技有限公司 四氢萘类化合物、其药物组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
WO2012068783A1 (en) 2010-11-25 2012-05-31 Shan Dong Luye Pharmaceutical Co., Ltd. Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
US9499526B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2016014242A1 (en) 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
US9956201B2 (en) * 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Also Published As

Publication number Publication date
ES2855976T3 (es) 2021-09-27
WO2018014277A1 (zh) 2018-01-25
CN109415335B (zh) 2020-06-05
US11111227B2 (en) 2021-09-07
AU2016415408B2 (en) 2019-04-11
US20190330177A1 (en) 2019-10-31
RU2717542C1 (ru) 2020-03-24
KR20190031314A (ko) 2019-03-25
EP3489227B1 (en) 2020-10-21
CA3030043C (en) 2021-01-19
AU2016415408A1 (en) 2019-01-17
US10669249B2 (en) 2020-06-02
JP6751208B2 (ja) 2020-09-02
EP3489227A4 (en) 2020-01-22
EP3489227A1 (en) 2019-05-29
RU2717542C9 (ru) 2020-08-12
SG11201811543XA (en) 2019-02-27
US20200255396A1 (en) 2020-08-13
CA3030043A1 (en) 2018-01-25
CN109415335A (zh) 2019-03-01
JP2019523297A (ja) 2019-08-22
PH12018550212A1 (en) 2019-10-28
PL3489227T3 (pl) 2021-05-04
MY195897A (en) 2023-02-27

Similar Documents

Publication Publication Date Title
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
DOP2015000170A (es) Compuestos químicos
BR112019001035A2 (pt) beenato de rotigotina, e método de preparação e uso do mesmo
BR112016001446A8 (pt) composições terapêuticas, produto de combinação, uso in vitro de flecainida e flecainida
DOP2016000253A (es) Nuevos compuestos
BR112015008297A2 (pt) antagonistas de mglu2/3 para o tratamento de distúrbios autistas
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
AR106364A1 (es) Derivados de insulina y sus usos médicos
BR112015030431A2 (pt) formulação de liberação modificada
BR112018012218A2 (pt) preparação de liberação prolongada de apremilast
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
PE20151607A1 (es) Formulaciones de compuestos organicos
CL2015003761A1 (es) Derivados de etinil como antagonistas de receptor metabotrópico de glutamato.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2680 DE 17-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.